FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080218091> ?p ?o ?g. }

• W3080218091 endingPage "823" @default.
• W3080218091 startingPage "814" @default.
• W3080218091 abstract "Diffuse large B-cell lymphoma (DLBCL) is the most widespread type of non-Hodgkin lymphoma (NHL). As the most aggressive form of the DLBCL, the activated B-cell-like (ABC) subtype is often resistant to standard chemotherapies. Bruton's tyrosine kinase (BTK) inhibitor ibrutinib provides a potential therapeutic approach for the DLBCL but fails to improve the outcome in the phase III trial. In the current study, we investigated the molecular mechanisms underlying ibrutinib resistance and explored new combination therapy with ibrutinib. We generated an ibrutinib-resistant ABC-DLBCL cell line (OCI-ly10-IR) through continuous exposure to ibrutinib. Transcriptome analysis of the parental and ibrutinib-resistant cell lines revealed that the ibrutinib-resistant cells had significantly lower expression of the unfolded protein response (UPR) marker genes. Overexpression of one UPR branch-XBP1s greatly potentiated ibrutinib-induced apoptosis in both sensitive and resistant cells. The UPR inhibitor tauroursodeoxycholic acid (TUDCA) partially reduced the apoptotic rate induced by the ibrutinib in sensitive cells. The UPR activator 2-deoxy-D-glucose (2-DG) in combination with the ibrutinib triggered even greater cell growth inhibition, apoptosis, and stronger calcium (Ca2+) flux inhibition than either of the agents alone. A combination treatment of ibrutinib (15 mg·kg-1·d-1, po.) and 2-DG (500 mg/kg, po, b.i.d.) synergistically retarded tumor growth in NOD/SCID mice bearing OCI-ly10-IR xenograft. In addition, ibrutinib induced the UPR in the sensitive cell lines but not in the resistant cell lines of the DLBCL. There was also a combined synergistic effect in the primary resistant DLBCL cell lines. Overall, our results suggest that targeting the UPR could be a potential combination strategy to overcome ibrutinib resistance in the DLBCL." @default.
• W3080218091 created "2020-09-01" @default.
• W3080218091 creator A5004338630 @default.
• W3080218091 creator A5008391749 @default.
• W3080218091 creator A5017120098 @default.
• W3080218091 creator A5018633041 @default.
• W3080218091 creator A5039081075 @default.
• W3080218091 creator A5052759717 @default.
• W3080218091 creator A5052840612 @default.
• W3080218091 creator A5057829636 @default.
• W3080218091 creator A5059175803 @default.
• W3080218091 creator A5063392279 @default.
• W3080218091 creator A5066066360 @default.
• W3080218091 creator A5066942670 @default.
• W3080218091 creator A5079629255 @default.
• W3080218091 creator A5081663262 @default.
• W3080218091 creator A5087555211 @default.
• W3080218091 date "2020-08-27" @default.
• W3080218091 modified "2023-10-04" @default.
• W3080218091 title "Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma" @default.
• W3080218091 cites W1020989877 @default.
• W3080218091 cites W1856950927 @default.
• W3080218091 cites W1970090817 @default.
• W3080218091 cites W1975682198 @default.
• W3080218091 cites W1979816280 @default.
• W3080218091 cites W1989711933 @default.
• W3080218091 cites W1993345471 @default.
• W3080218091 cites W1993401552 @default.
• W3080218091 cites W2001343785 @default.
• W3080218091 cites W2006057010 @default.
• W3080218091 cites W2027648780 @default.
• W3080218091 cites W2028681024 @default.
• W3080218091 cites W2048209604 @default.
• W3080218091 cites W2052645281 @default.
• W3080218091 cites W2082710624 @default.
• W3080218091 cites W2090475693 @default.
• W3080218091 cites W2102217018 @default.
• W3080218091 cites W2104039873 @default.
• W3080218091 cites W2105066639 @default.
• W3080218091 cites W2108234281 @default.
• W3080218091 cites W2114570899 @default.
• W3080218091 cites W2121743948 @default.
• W3080218091 cites W2130410032 @default.
• W3080218091 cites W2138601221 @default.
• W3080218091 cites W2146290346 @default.
• W3080218091 cites W2147246240 @default.
• W3080218091 cites W2148766088 @default.
• W3080218091 cites W2154326312 @default.
• W3080218091 cites W2169445756 @default.
• W3080218091 cites W2192080449 @default.
• W3080218091 cites W2204180336 @default.
• W3080218091 cites W2297773450 @default.
• W3080218091 cites W2412844774 @default.
• W3080218091 cites W2419422146 @default.
• W3080218091 cites W2587128226 @default.
• W3080218091 cites W2605336808 @default.
• W3080218091 cites W2606860547 @default.
• W3080218091 cites W2746608388 @default.
• W3080218091 cites W2785764393 @default.
• W3080218091 cites W2788525877 @default.
• W3080218091 cites W2791884959 @default.
• W3080218091 cites W2792386849 @default.
• W3080218091 cites W2792579163 @default.
• W3080218091 cites W2804958100 @default.
• W3080218091 cites W2891722856 @default.
• W3080218091 cites W2923453543 @default.
• W3080218091 cites W2964798481 @default.
• W3080218091 cites W2993793724 @default.
• W3080218091 cites W3003868291 @default.
• W3080218091 cites W914588906 @default.
• W3080218091 doi "https://doi.org/10.1038/s41401-020-00505-3" @default.
• W3080218091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8115113" @default.
• W3080218091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32855532" @default.
• W3080218091 hasPublicationYear "2020" @default.
• W3080218091 type Work @default.
• W3080218091 sameAs 3080218091 @default.
• W3080218091 citedByCount "5" @default.
• W3080218091 countsByYear W30802180912021 @default.
• W3080218091 countsByYear W30802180912022 @default.
• W3080218091 countsByYear W30802180912023 @default.
• W3080218091 crossrefType "journal-article" @default.
• W3080218091 hasAuthorship W3080218091A5004338630 @default.
• W3080218091 hasAuthorship W3080218091A5008391749 @default.
• W3080218091 hasAuthorship W3080218091A5017120098 @default.
• W3080218091 hasAuthorship W3080218091A5018633041 @default.
• W3080218091 hasAuthorship W3080218091A5039081075 @default.
• W3080218091 hasAuthorship W3080218091A5052759717 @default.
• W3080218091 hasAuthorship W3080218091A5052840612 @default.
• W3080218091 hasAuthorship W3080218091A5057829636 @default.
• W3080218091 hasAuthorship W3080218091A5059175803 @default.
• W3080218091 hasAuthorship W3080218091A5063392279 @default.
• W3080218091 hasAuthorship W3080218091A5066066360 @default.
• W3080218091 hasAuthorship W3080218091A5066942670 @default.
• W3080218091 hasAuthorship W3080218091A5079629255 @default.
• W3080218091 hasAuthorship W3080218091A5081663262 @default.
• W3080218091 hasAuthorship W3080218091A5087555211 @default.
• W3080218091 hasBestOaLocation W30802180911 @default.
• W3080218091 hasConcept C185592680 @default.

• next